The estimated Net Worth of Peter Libby is at least $299 Thousand dollars as of 9 July 2021. Peter Libby owns over 25,000 units of XBiotech Inc stock worth over $161,750 and over the last 5 years he sold XBIT stock worth over $0. In addition, he makes $137,000 as Independent Director at XBiotech Inc.
Peter has made over 1 trades of the XBiotech Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 25,000 units of XBIT stock worth $194,000 on 9 July 2021.
The largest trade he's ever made was exercising 25,000 units of XBiotech Inc stock on 9 July 2021 worth over $194,000. On average, Peter trades about 3,571 units every 0 days since 2019. As of 9 July 2021 he still owns at least 25,000 units of XBiotech Inc stock.
You can see the complete history of Peter Libby stock trades at the bottom of the page.
Dr. Peter Libby M.D. serves as Independent Director of the Company. Dr. Libby has been a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH) Since October 1990. He became a full professor in March 1996 and since December 1998 has been the Mallinckrodt Professor of Medicine at Harvard Medical School (HMS). Dr. Libby received his medical degree from the University of California, San Diego School of Medicine. He completed a residency in internal medicine and a fellowship in cardiovascular disease at Peter Bent Brigham Hospital (now BWH). He also completed a research fellowship in cellular physiology at HMS. Dr. Libby is board certified in internal medicine and cardiovascular disease. The author of some 400 original peer-reviewed publications, some 450 reviews, chapters and other publications, Dr. Libby also serves as an editor of the leading textbook of cardiovascular medicine. Dr. Libby's clinical and research interests include vascular biology, atherosclerosis and preventive cardiology. The research laboratory that Dr. Libby directs studies the messengers created by the body that may produce arterial plaque and blockages, as well as normal and abnormal function of smooth muscle and endothelial cells. Dr. Libby is perennially named a top cardiologist. His research has received funding from the American Heart Association and National Institutes of Health. Dr. Libby has received research recognitions on four continents including the highest research awards from the American Heart Association and American College of Cardiology, the Gold Medal of the European Society of Cardiology, the Anitchkow award from the European Atherosclerosis Society, The Ernst Jung Gold Medal for Medicine, and the Earl Benditt award for vascular biology.
As the Independent Director of XBiotech Inc, the total compensation of Peter Libby at XBiotech Inc is $137,000. There are 6 executives at XBiotech Inc getting paid more, with John Simard having the highest compensation of $10,810,400.
Peter Libby is 73, he's been the Independent Director of XBiotech Inc since 2019. There are no older and 9 younger executives at XBiotech Inc.
Over the last 9 years, insiders at XBiotech Inc have traded over $50,443,920 worth of XBiotech Inc stock and bought 1,428,502 units worth $11,921,113 . The most active insiders traders include Street Financial S.A. Bay, Fondation Rennes, and W Thorpe Mckenzie. On average, XBiotech Inc executives and independent directors trade stock every 48 days with the average trade being worth of $1,053,782. The most recent stock trade was executed by W Thorpe Mckenzie on 16 December 2021, trading 250,000 units of XBIT stock currently worth $2,500,000.
xbiotech is developing a first-in-class monoclonal antibody (mabp1) to inhibit chronic inflammation. chronic (sterile) inflammatory responses are involved in the progression of many serious and common diseases. mabp1 is being investigated in many important areas of medicine, including: cancer, leukemia (phase 1); type 2 diabetes (phase2); psoriasis (phase 2); and vascular disease (phase 2). mabp1 is a true human™ antibody cloned from a natural human immune response and—unlike currently marketed antibodies—it has not undergone any modification to alter its function. it has exhibited the best potential tolerability and safety during the clinical trials. xbiotech has established a current good manufacturing practices (cgmp) program to commercialize its lead product candidate. the company has purchased land and designed a commercial-scale plant with 25,000l total bioreactor capacity. construction of the facility is planned to commence in 4th quarter 2011..
XBiotech Inc executives and other stock owners filed with the SEC include: